LOXONIN

LOXONIN is a Japanese pharmaceutical brand associated primarily with loxoprofen sodium, a non-steroidal anti-inflammatory drug (NSAID). The medicine is used to relieve pain and reduce inflammation, including symptoms associated with headaches, toothache, menstrual pain, musculoskeletal pain, back pain, and fever, depending on the formulation and approved indication. Its principal pharmacological action comes from inhibition of prostaglandin production through cyclooxygenase pathways. Loxoprofen is commonly described as a propionic-acid NSAID and is notable for being administered as a prodrug that is converted in the body to its active form. The brand originated in Japan as a prescription medicine developed by Sankyo, the pharmaceutical company that later became part of Daiichi Sankyo. The original prescription product is generally identified as Loxonin tablets. Over time, loxoprofen products expanded beyond the prescription channel. In Japan, consumer versions were introduced as over-the-counter medicines, allowing the brand to reach pharmacies and drugstores as well as hospitals and clinics. The Japanese OTC range has included tablet products and other formulations, with distinctions in strength, excipients, dosage instructions, and regulatory classification. LOXONIN occupies the everyday pain-relief segment rather than the specialist hospital-drug segment. Its brand identity is built around rapid, practical relief for common acute pain while retaining the clinical credibility of an established prescription medicine. The brand is especially recognizable in Japan, where "Loxonin" is often used in ordinary discussion as a reference to loxoprofen-based painkillers. The brand should not, however, be treated as synonymous with every loxoprofen product: generic medicines and products sold under other names may contain the same active ingredient, and approved indications vary by country and formulation. The principal safety considerations are those associated with NSAIDs. Loxoprofen products can cause gastrointestinal adverse effects and may carry risks involving bleeding, kidney function, allergic reactions, and cardiovascular or other complications in susceptible users. Product labeling commonly includes warnings concerning prolonged or excessive use, combination with other analgesics or NSAIDs, pregnancy or breastfeeding, pre-existing disease, and use in children or older adults. Exact contraindications, dosage limits, and pharmacy-sale conditions depend on the local product authorization. These issues have made consumer instructions and pharmacist consultation important parts of the brand's positioning. LOXONIN remains an active brand in Japan under the Daiichi Sankyo Healthcare organization, within the broader Daiichi Sankyo Group. Its portfolio has extended from prescription tablets to OTC pain-relief products and topical preparations in selected markets or product lines. Reliable public sources do not establish a single global headquarters for the brand, a standalone listing, or a separately reported brand revenue figure.

LOXONIN is the principal Japanese brand associated with loxoprofen sodium, an NSAID developed by Sankyo. The active substance was designed as a prodrug: it is converted after administration into an active metabolite that inhibits prostaglandin synthesis and thereby reduces pain, inflammation, and fever. This development approach became part of the medicine's clinical identity, although the brand's consumer communications focus more on practical pain relief than on detailed pharmacology. The product was introduced in Japan as a prescription medicine under the Loxonin name. Its initial role was in clinical treatment of pain and inflammatory symptoms, where physicians could prescribe loxoprofen tablets subject to Japanese labeling and medical supervision. Sankyo subsequently became part of the corporate history that led to Daiichi Sankyo, and responsibility for consumer healthcare products later came to be associated with Daiichi Sankyo Healthcare. A major turning point came in 2006, when loxoprofen was made available in Japan as an OTC medicine through the Loxonin S range. This change broadened the brand's distribution from medical institutions to pharmacies and drugstores and positioned it for self-treatment of common short-term pain. The OTC transition also required consumer-facing instructions and restrictions concerning dosage, duration of use, contraindications, interactions, and the circumstances in which a customer should consult a medical professional. The Japanese range subsequently expanded beyond the original tablet concept. Variants have been differentiated by formulation and accompanying ingredients, including products marketed for stronger or more targeted consumer needs. Topical preparations have also been associated with the broader loxoprofen product family. Because product approvals differ by jurisdiction, the exact composition, indications, and legal status of products sold under the LOXONIN name cannot be assumed to be identical outside Japan. LOXONIN's commercial strength comes from the combination of prescription heritage, broad recognition in Japan, and availability in the self-medication channel. It competes with other NSAIDs and analgesic brands, including products based on ibuprofen, naproxen, diclofenac, acetaminophen, and generic loxoprofen. The brand's principal limitations are also typical of NSAIDs: gastrointestinal, renal, allergic, bleeding, and cardiovascular risks can be clinically important, particularly with inappropriate use or in people with relevant medical conditions. Japanese labeling therefore emphasizes short-term use, avoidance of duplicate NSAID therapy, and consultation with pharmacists or physicians when symptoms persist or risk factors are present. The brand remains active under Daiichi Sankyo Healthcare and the wider Daiichi Sankyo Group. Publicly available sources do not provide a separately reported LOXONIN revenue figure, standalone corporate listing, or complete worldwide product chronology.

1. 2006OTC launch of Loxonin S

   An OTC Loxonin product was introduced in Japan, extending access to pharmacies and drugstores and making the brand a prominent self-medication pain-relief product.

   Source
2. Prescription introduction in Japan

   Loxoprofen sodium was commercialized in Japan under the Loxonin brand as a prescription analgesic and anti-inflammatory medicine. The exact initial launch year is not stated consistently in the available reference material.

   Source
3. Expansion into additional formulations

   The brand family expanded with additional oral variants and topical loxoprofen products. Individual launch dates and market availability differ by product.

   Source

A trusted Japanese pain-relief brand combining prescription heritage with convenient pharmacy and drugstore availability. Its consumer positioning emphasizes effective relief for common acute pain, while its NSAID status requires prominent safety and dosage guidance.

• Loxonin tabletsPrescription NSAID

  The prescription form of the brand is based on loxoprofen sodium and is used for relief of pain and inflammatory symptoms under the applicable Japanese medical labeling. It represents the brand's clinical heritage and is distinct from OTC variants in authorization, instructions, and access conditions.

• Loxonin SOTC oral analgesic2006

  Loxonin S is the core Japanese OTC presentation of loxoprofen sodium. It is intended for short-term relief of common pain and fever within the approved labeling. The product brought the prescription-associated brand into consumer pharmacy distribution and is sold with warnings concerning dosage, duration, contraindications, and duplicate use of NSAIDs.

• Loxonin S PlusOTC combination analgesic

  Loxonin S Plus is an OTC variant in the Japanese range that combines loxoprofen sodium with an additional ingredient. The formulation is intended to provide a differentiated consumer option while retaining the brand's loxoprofen-based analgesic foundation. Composition and approved uses should be checked against current package labeling.

• Loxonin S PremiumOTC combination analgesic

  Loxonin S Premium is a higher-positioned OTC formulation within the Japanese Loxonin family. It uses loxoprofen as its principal analgesic component alongside formulation-specific ingredients. The product is marketed for consumers seeking a differentiated oral pain-relief option, but its permitted indications and precautions remain defined by Japanese regulatory labeling.

• Loxonin topical productsTopical NSAID

  Topical products associated with the Loxonin name deliver loxoprofen through the skin for localized pain and inflammation, where authorized. Depending on the specific presentation, the range may include gels, tapes, or other external-use formats. Topical administration does not eliminate NSAID-related precautions, and users are expected to follow product-specific warnings.

• 2006Move from prescription heritage into OTC self-medicationStrategy

  Loxoprofen had established a prescription presence in Japan, but consumer access to the ingredient was limited by the prescription channel.

  What changed. Daiichi Sankyo introduced the Loxonin S OTC product in Japan, placing the established active ingredient into pharmacy and drugstore distribution.

  Aftermath. The move broadened the brand's consumer reach and made LOXONIN one of Japan's recognizable OTC analgesic brands.

  Source
• Development of differentiated OTC and topical variantsProduct launch

  The OTC pain-relief market includes consumers seeking different strengths, combinations, and routes of administration.

  What changed. The Loxonin family added variants such as Loxonin S Plus, Loxonin S Premium, and topical products where authorized.

  Aftermath. The product family addressed more consumer use cases while retaining loxoprofen sodium as its central brand association.

  Source

• 2011Loxoprofen becomes available in Japan as an over-the-counter medicine under the Loxonin S brand

  Daiichi Sankyo Healthcare introduced Loxonin S, bringing the loxoprofen active ingredient from its established prescription context into Japanese self-medication. The launch made the brand available through pharmacies and drugstores for labeled indications such as headache, menstrual pain, toothache, musculoskeletal pain, and fever.

  Product launch
  Source
• 2006Loxoprofen enters the Japanese over-the-counter market through Loxonin S

  Daiichi Sankyo launched an OTC version of the established loxoprofen product in Japan, extending the brand from prescription use into self-medication and pharmacy retail.

  Product launch
  Source
• LOXONIN expands its OTC pain-relief range

  The Japanese brand developed additional OTC variants and formulations, including products differentiated by dosage, combination ingredients, and topical delivery. Exact launch timing varies by product and is not consistently stated in the available reference material.

  Product generationProduct launch
  Source
• Japanese regulators strengthen warnings concerning serious adverse reactions to loxoprofen-containing medicines

  Regulatory safety information for loxoprofen-containing medicines has addressed potentially serious gastrointestinal, renal, hypersensitivity, and other adverse reactions. The information is reflected in prescribing information and Japanese OTC labeling rather than representing a distinct brand scandal.

  Regulation
  Source

1. Loxonin official consumer product site
2. Loxoprofen overview
3. Daiichi Sankyo Healthcare corporate site
4. Japanese regulators strengthen warnings concerning serious adverse reactions to loxoprofen-containing medicines